REGEND001 Autologous Basal Layer Stem Cell Transplantation for Bronchiectasis: A Translational Application Study
Status: Recruiting
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This clinical trial aims to evaluate the safety and efficacy of REGEND001, an autologous basal layer stem cell transplantation therapy, in patients with chronic structural lung disease (bronchiectasis). The treatment involves harvesting bronchial basal layer stem cells from the patient, expanding them ex vivo, and reintroducing them via bronchoscopic infusion to repair damaged lung tissue.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 25
Maximum Age: 80
Healthy Volunteers: f
View:
• Age 25-80 years.
• Confirmed diagnosis of bronchiectasis.
• FEV1 ≥35% predicted; DLCO ≥30% and \<80% predicted.
Locations
Other Locations
China
Ruijin Hospital Hainan Branch, Shanghai Jiao Tong University School of Medicine
RECRUITING
Qionghai
Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
RECRUITING
Shanghai
Time Frame
Start Date: 2025-06-18
Estimated Completion Date: 2029-05-30
Participants
Target number of participants: 10
Treatments
Experimental: Bronchiectasis patients
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital